These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38688000)

  • 21. In vivo quantification of formulated and chemically modified small interfering RNA by heating-in-Triton quantitative reverse transcription polymerase chain reaction (HIT qRT-PCR).
    Landesman Y; Svrzikapa N; Cognetta A; Zhang X; Bettencourt BR; Kuchimanchi S; Dufault K; Shaikh S; Gioia M; Akinc A; Hutabarat R; Meyers R
    Silence; 2010 Aug; 1(1):16. PubMed ID: 20731861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing.
    Chen Q; Zhang Y; Yin H
    Adv Drug Deliv Rev; 2021 Jan; 168():246-258. PubMed ID: 33122087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deformability Calculation for Estimation of the Relative Stability of Chemically Modified RNA Duplexes.
    Masaki Y; Sekine M; Seio K
    Curr Protoc Nucleic Acid Chem; 2017 Mar; 68():7.27.1-7.27.10. PubMed ID: 28252179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemically Modified, α-Amino-3-hydroxy-5-methyl-4-isoxazole (AMPA) Receptor RNA Aptamers Designed for in Vivo Use.
    Huang Z; Wen W; Wu A; Niu L
    ACS Chem Neurosci; 2017 Nov; 8(11):2437-2445. PubMed ID: 28872832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancements in clinical RNA therapeutics: Present developments and prospective outlooks.
    Saw PE; Song E
    Cell Rep Med; 2024 May; 5(5):101555. PubMed ID: 38744276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemically Modified Messenger RNA: Modified RNA Application for Treatment of Achilles Tendon Defects.
    Herbst E; Imhoff FB; Foehr P; Milz S; Plank C; Rudolph C; Hasenpusch G; Geiger JP; Aneja MK; Groth K; Vogt S; Imhoff AB; Schmitt A
    Tissue Eng Part A; 2019 Jan; 25(1-2):113-120. PubMed ID: 29676227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Dawning of a New Enterprise: RNA Therapeutics for the Skin.
    Kieser RE; Khan S; Bejar N; Kiss DL
    J Dermatol Skin Sci; 2023; 5(1):4-13. PubMed ID: 38435714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development and technologies of RNA therapeutics.
    Vuong HL; Lan CT; Le HTT
    Prog Mol Biol Transl Sci; 2024; 203():13-39. PubMed ID: 38359995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Facile Approach for Generating Chemically Modified CRISPR/Cas9 RNA.
    Scott T; Soemardy C; Morris KV
    Mol Ther Nucleic Acids; 2020 Mar; 19():1176-1185. PubMed ID: 32069700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics.
    Godin B; Tasciotti E; Liu X; Serda RE; Ferrari M
    Acc Chem Res; 2011 Oct; 44(10):979-89. PubMed ID: 21902173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.
    Desjardins JP; Sproat BS; Beijer B; Blaschke M; Dunkel M; Gerdes W; Ludwig J; Reither V; Rupp T; Iversen PL
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1419-27. PubMed ID: 8819529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemically modified siRNA: tools and applications.
    Watts JK; Deleavey GF; Damha MJ
    Drug Discov Today; 2008 Oct; 13(19-20):842-55. PubMed ID: 18614389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNA Chemistry for RNA Biology.
    Röthlisberger P; Berk C; Hall J
    Chimia (Aarau); 2019 May; 73(5):368-373. PubMed ID: 31118118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canonical and non-canonical barriers facing antimiR cancer therapeutics.
    Cheng CJ; Saltzman WM; Slack FJ
    Curr Med Chem; 2013; 20(29):3582-93. PubMed ID: 23745563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical Synthesis and Biological Application of Modified Oligonucleotides.
    Glazier DA; Liao J; Roberts BL; Li X; Yang K; Stevens CM; Tang W
    Bioconjug Chem; 2020 May; 31(5):1213-1233. PubMed ID: 32227878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma growth in non-chemically modified translucid bacterial nanocellulose hollow and compartimentalized spheres.
    Fucina G; Cesca K; Berti FV; Biavatti MW; Porto LM
    Biochim Biophys Acta Gen Subj; 2022 Sep; 1866(9):130183. PubMed ID: 35661803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic RNA Therapeutics in Cancer.
    Han Y; Shin SH; Lim CG; Heo YH; Choi IY; Kim HH
    J Pharmacol Exp Ther; 2023 Aug; 386(2):212-223. PubMed ID: 37188531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of chemically modified gold and silver clusters in gas phase.
    Hirata K; Tomihara R; Kim K; Koyasu K; Tsukuda T
    Phys Chem Chem Phys; 2019 Aug; 21(32):17463-17474. PubMed ID: 31363731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fast and simple purification of chemically modified hammerhead ribozymes using a lipophilic capture tag.
    Sproat BS; Rupp T; Menhardt N; Keane D; Beijer B
    Nucleic Acids Res; 1999 Apr; 27(8):1950-5. PubMed ID: 10101206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement of mRNA therapeutics: method development and validation challenges.
    Henderson N; Wilson A
    Bioanalysis; 2019 Nov; 11(21):2003-2010. PubMed ID: 31657232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.